In this study, 27 core targets were predicted for MSMY in the treatment of ALL, including triptolide, RAC-alpha serine/threonine-protein kinase (AKT1), vascular endothelial growth factor A, Caspase-3 (CASP3), Myc proto-oncogene protein and estrogen receptor 1. Here, AKT1 is linked to acute lymphoblastic leukemia.